ClinicalTrials.Veeva

Find clinical trials for Adenocarcinoma in Toronto, ON

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Carcinoma
Cancer
Pancreatic Cancer
Stomach Cancer
Colorectal Cancer
Prostatic Cancer
Esophageal Cancer

Adenocarcinoma trials near Toronto, ON, CAN:

Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma

This study is being done to answer the following question:Can the chance of gastroesophageal cancer growing or spreading be lowered by adding a drug...

Enrolling
Gastroesophageal Adenocarcinoma
Drug: Zanidatamab
Drug: Ramucirumab

Phase 2

Canadian Cancer Trials Group

Toronto, Ontario, Canada

Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2

and placebo in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).This study aims to explore whether blockade of Transforming Gr...

Active, not recruiting
Metastatic Pancreatic Ductal Adenocarcinoma
Drug: Gemcitabine
Drug: NIS793

Phase 3

Novartis
Novartis

Toronto, Ontario, Canada and 113 other locations

Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma

The standard or usual treatment for this disease consists of two chemotherapy drugs gemcitabine and nab-paclitaxel given together.

Active, not recruiting
Pancreatic Adenocarcinoma
Drug: Gemcitabine
Drug: Tremelimumab

Phase 2

Canadian Cancer Trials Group

Toronto, Ontario, Canada and 26 other locations

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

adenocarcinoma (GEA), biliary tract cancer (BTC), or colorectal cancer (CRC)....

Active, not recruiting
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Drug: Leucovorin
Drug: ZW25 (Zanidatamab)

Phase 2

Jazz Pharmaceuticals
Jazz Pharmaceuticals

Toronto, Ontario, Canada and 20 other locations

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (STAR-221)

first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma...

Enrolling
Advanced Upper Gastrointestinal Tract Adenocarcinoma
Drug: Capecitabine
Drug: Fluorouracil

Phase 3

Arcus Biosciences
Arcus Biosciences

Toronto, Canada and 212 other locations

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma...

Enrolling
Gastroesophageal Junction Cancer
Gastric Cancer
Drug: Apatinib
Drug: Ramucirumab+ paclitaxel

Phase 3

AstraZeneca
AstraZeneca

Toronto, Ontario, Canada and 118 other locations

A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight)

unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Why is this study being done? SPOTLIGHT is a new clinical st...

Active, not recruiting
Metastatic Gastric Adenocarcinoma or Cancer
Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
Drug: placebo
Drug: oxaliplatin

Phase 3

Astellas
Astellas

Toronto, Ontario, Canada and 219 other locations

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

The purpose of this study is to assess the efficacy and safety of lenvatinib (E7080/MK-7902) plus pembrolizumab (MK-3475) plus chemotherapy compared...

Active, not recruiting
Advanced/Metastatic Gastroesophageal Adenocarcinoma
Drug: Oxaliplatin
Biological: Lenvatinib

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Hamilton, Ontario, Canada and 176 other locations

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (HERIZON-GEA-01)

This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzum...

Enrolling
Gastroesophageal Adenocarcinoma
Esophageal Adenocarcinoma
Drug: 5-Fluorouracil
Drug: Zanidatamab

Phase 3

Jazz Pharmaceuticals
Jazz Pharmaceuticals

Toronto, Canada and 314 other locations

Phase I/IIa Study for AZD5335 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors (FONTANA)

This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer age...

Enrolling
Lung Adenocarcinoma
Ovarian Cancer
Drug: AZD5305
Drug: AZD5335

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Toronto, Ontario, Canada and 38 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems